Insu Kim, Sun Ha Choi, Shin Yup Lee, Seung Soo Yoo, Ji Eun Park, Kyeong-Cheol Shin, Jong Geol Jang, Kyung Soo Hong, Yong Shik Kwon, Sun Hyo Park, Keum-Ju Choi, Chi Young Jung, Mi-Hyun Kim, Soo Han Kim, Hee Yun Seol, Jehun Kim, Jin-Han Park, Tae Hoon Kim, Jung Seop Eom, June Hong Ahn
BACKGROUND/AIM: Durvalumab consolidation is less effective in patients with epidermal growth factor receptor mutant (EGFR M+) NSCLC. Studies of durvalumab on EGFR M+ NSCLC as an expression of programmed death-ligand 1 (PD-L1) expression are limited. The purpose of this study was to determine the effect of durvalumab on PD-L1 expression in EGFR M+ patients. PATIENTS AND METHODS: This study included 249 unresectable stage III NSCLC patients treated with durvalumab...
October 2024: Anticancer Research